Thomas Laurent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Laurent has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Cynthia Fourgeux
Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000, Nantes, France
4 shared publications- Jeremie Poschmann
Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, France
4 shared publications Alexis Broquet
Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France
2 shared publications- Antoine Roquilly
Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
2 shared publications Cecile Poulain
Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France
2 shared publications- Christelle Harly
Université de Nantes, INSERM, CNRS, CRCI2NA, Nantes, France
2 shared publications
Latest Publications
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Développement de nouvelles approches pour l’analyses des interactions cellulaires dans les maladies immunitaires
Le développement des technologies de séquençage a ouvert la voie vers la caractérisation des mécanismes immunopathologiques en atteignant la précision des cellules uniques. L’application de ce type d’analyses transcriptomiques à des échantillons de cellules circulantes provenant de receveur de greffe de rein nous a permis de suivre de manière longitudinale les dynamiques post transplantation des différentes populations immunitaires. Nous avons mis en avant l’émergence d’une signature d’activation précoce préférentiellement exprimée par les cellules immunitaires des patients qui subissent un rejet de greffe par la suite. Cette signature semble indiquer un recrutement favorisé de lymphocytes T et monocytes via l’axe CXCR4- CXCL12 qui participerait à la détérioration des tissus menant au rejet. Dans le second projet, l’application du séquençage en cellule unique a permis d’étudier les programmes moléculaires en jeu au sein des tissus d’iléons de patients atteints de la maladie de Crohn. Par l’adaptation de l’algorithme de Metacell combinée à une analyse de modules de gènes sur notre jeu de données, il a été possible d’identifier avec précision une hétérogénéité de profils au sein des macrophages avec la présence de signatures inflammatoires et pro-fibrotiques enrichies chez les patients ne répondant pas au traitement clinique d’anti-TNFa actuel. Ces résultats proposent de nouvelles pistes de compréhension pour expliquer les différences de réponses de patients et permettent d’envisager de nouveaux traitements plus adaptées pour cibler les programmes moléculaires actives chez les patients non répondeurs.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Développement de nouvelles approches pour l’analyses des interactions cellulaires dans les maladies immunitaires
Le développement des technologies de séquençage a ouvert la voie vers la caractérisation des mécanismes immunopathologiques en atteignant la précision des cellules uniques. L’application de ce type d’analyses transcriptomiques à des échantillons de cellules circulantes provenant de receveur de greffe de rein nous a permis de suivre de manière longitudinale les dynamiques post transplantation des différentes populations immunitaires. Nous avons mis en avant l’émergence d’une signature d’activation précoce préférentiellement exprimée par les cellules immunitaires des patients qui subissent un rejet de greffe par la suite. Cette signature semble indiquer un recrutement favorisé de lymphocytes T et monocytes via l’axe CXCR4- CXCL12 qui participerait à la détérioration des tissus menant au rejet. Dans le second projet, l’application du séquençage en cellule unique a permis d’étudier les programmes moléculaires en jeu au sein des tissus d’iléons de patients atteints de la maladie de Crohn. Par l’adaptation de l’algorithme de Metacell combinée à une analyse de modules de gènes sur notre jeu de données, il a été possible d’identifier avec précision une hétérogénéité de profils au sein des macrophages avec la présence de signatures inflammatoires et pro-fibrotiques enrichies chez les patients ne répondant pas au traitement clinique d’anti-TNFa actuel. Ces résultats proposent de nouvelles pistes de compréhension pour expliquer les différences de réponses de patients et permettent d’envisager de nouveaux traitements plus adaptées pour cibler les programmes moléculaires actives chez les patients non répondeurs.
- Open Access
A JAK-STAT-activated myeloid hub at ulceration sites underlies resistance to anti-TNF therapy in Crohn’s disease
Despite major advances in immunotherapies, durable disease control in immune-mediated inflammatory diseases (IMIDs) is frequently limited by resistance driven by maladaptive immune programs, resulting in progressive tissue damage. Myeloid cells are central effectors across IMIDs, including inflammatory bowel disease (IBD), yet how discrete myeloid states govern disease progression and therapeutic response remains incompletely defined. Here, using integrative single-cell transcriptomic and molecular analyses of inflamed human ileum in Crohn’s disease (CD), we identify combinatorial transcriptional programs that revealed previously unrecognized axes of monocyte-macrophage (mo-mac) heterogeneity. These myeloid states and programs were conserved and validated across multiple independent cohorts. We delineate a pathogenic mo-mac subset, interferon-associated inflammatory monocytes (IFIM), shaped by convergent NF-κB and IFNγ signaling and enriched in advanced disease. Baseline abundance of IFIM programs predicted resistance to anti-TNF therapy and severe postoperative recurrence, with IFIM-derived ligands sustaining epithelial injury. IFIM exhibited robust JAK–STAT activation, indicating susceptibility to JAK inhibition with clinically approved agents, including upadacitinib. Exemplified by IFIM-driven inflammation, these findings identify pathogenic myeloid state remodeling as a molecular basis of anti-TNF resistance and provide a framework for mechanism-guided therapeutic strategies across chronic inflammatory diseases.
Open AccessA JAK-STAT-activated myeloid hub at ulceration sites underlies resistance to anti-TNF therapy in Crohn’s disease
Despite major advances in immunotherapies, durable disease control in immune-mediated inflammatory diseases (IMIDs) is frequently limited by resistance driven by maladaptive immune programs, resulting in progressive tissue damage. Myeloid cells are central effectors across IMIDs, including inflammatory bowel disease (IBD), yet how discrete myeloid states govern disease progression and therapeutic response remains incompletely defined. Here, using integrative single-cell transcriptomic and molecular analyses of inflamed human ileum in Crohn’s disease (CD), we identify combinatorial transcriptional programs that revealed previously unrecognized axes of monocyte-macrophage (mo-mac) heterogeneity. These myeloid states and programs were conserved and validated across multiple independent cohorts. We delineate a pathogenic mo-mac subset, interferon-associated inflammatory monocytes (IFIM), shaped by convergent NF-κB and IFNγ signaling and enriched in advanced disease. Baseline abundance of IFIM programs predicted resistance to anti-TNF therapy and severe postoperative recurrence, with IFIM-derived ligands sustaining epithelial injury. IFIM exhibited robust JAK–STAT activation, indicating susceptibility to JAK inhibition with clinically approved agents, including upadacitinib. Exemplified by IFIM-driven inflammation, these findings identify pathogenic myeloid state remodeling as a molecular basis of anti-TNF resistance and provide a framework for mechanism-guided therapeutic strategies across chronic inflammatory diseases.
- Open Access
- 7 October 2024
- Published by Springer Nature in Nature Immunology
- Vol. 25 (11) , 2167
Author Correction: Sepsis-trained macrophages promote antitumoral tissue-resident T cells
- 7 October 2024
- Published by Springer Nature in Nature Immunology
- Vol. 25 (11) , 2167
Open AccessAuthor Correction: Sepsis-trained macrophages promote antitumoral tissue-resident T cells
- 29 April 2024
- Published by Springer Nature in Nature Immunology
- Vol. 25 (5) , 802-819
Sepsis-trained macrophages promote antitumoral tissue-resident T cells
Sepsis induces immune alterations, which last for months after the resolution of illness. The effect of this immunological reprogramming on the risk of developing cancer is unclear. Here we use a national claims database to show that sepsis survivors had a lower cumulative incidence of cancers than matched nonsevere infection survivors. We identify a chemokine network released from sepsis-trained resident macrophages that triggers tissue residency of T cells via CCR2 and CXCR6 stimulations as the immune mechanism responsible for this decreased risk of de novo tumor development after sepsis cure. While nonseptic inflammation does not provoke this network, laminarin injection could therapeutically reproduce the protective sepsis effect. This chemokine network and CXCR6 tissue-resident T cell accumulation were detected in humans with sepsis and were associated with prolonged survival in humans with cancer. These findings identify a therapeutically relevant antitumor consequence of sepsis-induced trained immunity.
- 29 April 2024
- Published by Springer Nature in Nature Immunology
- Vol. 25 (5) , 802-819
Sepsis-trained macrophages promote antitumoral tissue-resident T cells
Sepsis induces immune alterations, which last for months after the resolution of illness. The effect of this immunological reprogramming on the risk of developing cancer is unclear. Here we use a national claims database to show that sepsis survivors had a lower cumulative incidence of cancers than matched nonsevere infection survivors. We identify a chemokine network released from sepsis-trained resident macrophages that triggers tissue residency of T cells via CCR2 and CXCR6 stimulations as the immune mechanism responsible for this decreased risk of de novo tumor development after sepsis cure. While nonseptic inflammation does not provoke this network, laminarin injection could therapeutically reproduce the protective sepsis effect. This chemokine network and CXCR6 tissue-resident T cell accumulation were detected in humans with sepsis and were associated with prolonged survival in humans with cancer. These findings identify a therapeutically relevant antitumor consequence of sepsis-induced trained immunity.
- Open Access
A Gene-expression Module Identifies Circulating Immune Cells with Enhanced Recruitment to Sites of Inflammation
Circulating immune cells are critical mediators of inflammation upon recruitment to tissues, yet how their gene expression state influences this recruitment is not well understood. Here, we report longitudinal single-cell transcriptome profiling of peripheral blood mononuclear cells in patients undergoing kidney transplantation rejection. We identify a novel gene expression module, termed ALARM (early activation transcription factor module), associated with transcriptional regulation, homing, and immune activation across multiple immune cell types. Circulating cells expressing this module are significantly reduced in patients experiencing graft rejection, a finding confirmed in a pig model of acute kidney transplantation rejection. Correspondingly, module expression is markedly increased in kidney grafts undergoing rejection, indicating preferential recruitment of ALARM-expressing cells to the inflamed tissue. Within this module, we identify the receptor CXCR4 and its ligand CXCL12, expressed in the graft, as a likely mechanism for recruitment. In vitro transwell assays combined with scRNA-seq reveal that this CXCR4-CXCL12 interaction is critical for T cell migration and upregulation of CD69, an early activation marker, and is accompanied by a metabolic switch towards glycolysis. Further exploration of publicly available transcriptomic data demonstrates that this module is generally expressed in healthy individuals and is strongly associated with responses to infection, including SARS-CoV-2 infection. This finding is further supported by experiments in a pneumonia mouse model, which confirm the recruitment of CXCR4-expressing T cells during lung infection. Moreover, we find that module expression is predictive of immune-mediated diseases. In summary, we have identified a key gene expression module in circulating immune cells that orchestrates their preferential recruitment to inflamed tissues, metabolic reprogramming, promoting tissue residency and effector functions. These insights advance our understanding of immune cell recruitment and activation mechanisms in transplant rejection and infectious diseases, with potential implications for therapeutic interventions.
Open AccessA Gene-expression Module Identifies Circulating Immune Cells with Enhanced Recruitment to Sites of Inflammation
Circulating immune cells are critical mediators of inflammation upon recruitment to tissues, yet how their gene expression state influences this recruitment is not well understood. Here, we report longitudinal single-cell transcriptome profiling of peripheral blood mononuclear cells in patients undergoing kidney transplantation rejection. We identify a novel gene expression module, termed ALARM (early activation transcription factor module), associated with transcriptional regulation, homing, and immune activation across multiple immune cell types. Circulating cells expressing this module are significantly reduced in patients experiencing graft rejection, a finding confirmed in a pig model of acute kidney transplantation rejection. Correspondingly, module expression is markedly increased in kidney grafts undergoing rejection, indicating preferential recruitment of ALARM-expressing cells to the inflamed tissue. Within this module, we identify the receptor CXCR4 and its ligand CXCL12, expressed in the graft, as a likely mechanism for recruitment. In vitro transwell assays combined with scRNA-seq reveal that this CXCR4-CXCL12 interaction is critical for T cell migration and upregulation of CD69, an early activation marker, and is accompanied by a metabolic switch towards glycolysis. Further exploration of publicly available transcriptomic data demonstrates that this module is generally expressed in healthy individuals and is strongly associated with responses to infection, including SARS-CoV-2 infection. This finding is further supported by experiments in a pneumonia mouse model, which confirm the recruitment of CXCR4-expressing T cells during lung infection. Moreover, we find that module expression is predictive of immune-mediated diseases. In summary, we have identified a key gene expression module in circulating immune cells that orchestrates their preferential recruitment to inflamed tissues, metabolic reprogramming, promoting tissue residency and effector functions. These insights advance our understanding of immune cell recruitment and activation mechanisms in transplant rejection and infectious diseases, with potential implications for therapeutic interventions.
- Open Access
- 19 February 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 255
Characterization of Rat ILCs Reveals ILC2 as the Dominant Intestinal Subset
Innate lymphoid cells (ILCs) are tissue-resident lymphocytes that lack antigen-specific receptors and exhibit innate effector functions such as cytokine production that play an important role in immediate responses to pathogens especially at mucosal sites. Mouse and human ILC subsets have been extensively characterized in various tissues and in blood. In this study, we present the first characterization of ILCs and ILC subsets in rat gut and secondary lymphoid organs using flow cytometry and single cell RNA sequencing. Our results show that phenotype and function of rat ILC subsets are conserved as compared to human and mouse ILCs. However, and in contrast to human and mouse, our study unexpectedly revealed that ILC2 and not ILC3 was the dominant ILC subset in the rat intestinal lamina propria. ILC2 predominance in the gut was independent of rat strain, sex or housing facility. In contrast, ILC3 was the predominant ILC subset in mesenteric lymph nodes and Peyer patches. In conclusion, our study demonstrates that in spite of highly conserved phenotype and function between mice, rat and humans, the distribution of ILC subsets in the intestinal mucosa is dependent on the species likely in response to both genetic and environmental factors.
- 19 February 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 255
Open AccessCharacterization of Rat ILCs Reveals ILC2 as the Dominant Intestinal Subset
Innate lymphoid cells (ILCs) are tissue-resident lymphocytes that lack antigen-specific receptors and exhibit innate effector functions such as cytokine production that play an important role in immediate responses to pathogens especially at mucosal sites. Mouse and human ILC subsets have been extensively characterized in various tissues and in blood. In this study, we present the first characterization of ILCs and ILC subsets in rat gut and secondary lymphoid organs using flow cytometry and single cell RNA sequencing. Our results show that phenotype and function of rat ILC subsets are conserved as compared to human and mouse ILCs. However, and in contrast to human and mouse, our study unexpectedly revealed that ILC2 and not ILC3 was the dominant ILC subset in the rat intestinal lamina propria. ILC2 predominance in the gut was independent of rat strain, sex or housing facility. In contrast, ILC3 was the predominant ILC subset in mesenteric lymph nodes and Peyer patches. In conclusion, our study demonstrates that in spite of highly conserved phenotype and function between mice, rat and humans, the distribution of ILC subsets in the intestinal mucosa is dependent on the species likely in response to both genetic and environmental factors.